Chronic Kidney Disease Drug Development (CKD3) focuses exclusively on overcoming challenges limiting the development of more efficacious and disease-modifying drugs against diabetic nephropathy, genetic and glomerular kidney disease.

Incorporating insights from 32 world class experts including regulatory updates from the FDA, and analysis of the results from CREDENCE by Janssen R&D; this uniquely specific forum assesses key clinical and translational hurdles and the hottest emerging research necessary to achieve the potential of next-generation CKD drugs.

Join 100 of your colleagues to accelerate the development and clinical validity of SGLT-2 inhibitors, antagonists of renal fibrosis and much more.